Aclaris Therapeutics Reports Phase 2 Bosakitug Miss and Advances Lichen Planus Trial
Aclaris Therapeutics reported that bosakitug failed to meet primary and secondary endpoints in its Phase 2 atopic dermatitis trial but was well tolerated. The company advanced its clinical pipeline, initiating a Phase 2b trial for modzatinib in lichen planus and planning Phase 1 and 2b trials for ATI-9494 and ATI-052, respectively, in 2027. According to the company, bosakitug showed target engagement and reduced immune-activation biomarkers.
How this was made

The 30-second read
Why it matters
The miss is likely to trigger a sell‑off, but the announced Phase 2b trials in lichen planus and upcoming IND filings may mitigate long‑term downside.
Market read
Immediate negative pressure on ACRS; longer‑term view depends on pipeline progress.
What to watch
Upcoming IND filing for ATI-9494 could provide upside if investors focus on pipeline depth.
Background
Aclaris Therapeutics (NASDAQ: ACRS) reported a Phase 2 trial miss for bosakitug in atopic dermatitis and announced new pipeline initiatives.
Ticker impact
Aclaris Therapeutics disclosed that its bosakitug Phase 2 trial missed primary and secondary endpoints, a material clinical setback.
likely downward pressure as market prices in the missed endpoints
Phase 2 miss is a primary disclosure with material impact on biotech valuation.
Market effects
May dampen sentiment for dermatology and immunology biotech peers.
Limited to US biotech sector.
Low global impact beyond sector.
Counterpoint
If the company can pivot to its lichen planus trial, the miss may be priced out quickly.
Key entities
- companyAclaris Therapeutics
Biotech firm developing dermatology and immunology therapies.

